New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
17:04 EDTSUPN, UTHRSupernus receives $2M milestone payment for launch of Orenitram
Supernus Pharmaceuticals (SUPN) announced that United Therapeutics Corporation (UTHR) has paid Supernus a $2M milestone payment under United Therapeutics' license agreement with Supernus. This payment was due upon the launch of Orenitram Extended-Release Tablets for the treatment of pulmonary arterial hypertension, in the United States. Orenitram utilizes a Supernus patented technology platform. In addition to the launch milestone, Supernus will receive royalties on net sales of Orenitram, and may become entitled to additional milestone payments.
News For SUPN;UTHR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 24, 2015
07:45 EDTSUPNFDA Pediatric Advisory Committee holds a meeting
The Committee discusses pediatric-focused safety reviews, as mandated by the FDA Safety and Innovation Act (FDASIA) for Eli Lilly's Cymbalta, Pfizer's Quillivant XR and Revatio, Johnson & Johnson's Risperdal, GlaxoSmithKline's Advair, HFA Altabax Ointment and Fluarix Quadrivalent, Supernus Pharmaceuticals' Oxtellar XR, Teva Pharmaceutical's Qnasl and Roche's Invirase. The Committee will also discuss the safety ongoing propriety of the humanitarian device exemption for the Medtronic Activa Dystonia Therapy and for the Liposorber LA-15 System in a meeting being held in Silver Spring, Maryland on March 24 at 8 am. Webcast Link
March 18, 2015
13:04 EDTSUPNSupernus management to meet with Piper Jaffray
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use